Orient Europharma Co., Ltd.

As of June 30, 2026, Orient Europharma Co., Ltd. carries a market capitalization of 3.95B, placing it among publicly traded companies globally. Its enterprise value stands at 7.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Orient Europharma Co., Ltd. has 86.75M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.85, and the price-to-book ratio stands at 0.76.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.04B versus a market cap of 3.95B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Orient Europharma Co., Ltd. maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.62, indicating elevated leverage, while an interest coverage ratio of -2.32 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Orient Europharma Co., Ltd. posted a negative return on equity (ROE) of -10.08, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.81, reflecting losses generated across the asset base. The company generates approximately 5.58M in revenue per employee across its workforce of 834.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.95 indicates how many times Orient Europharma Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Orient Europharma Co., Ltd. recorded 157.18M in income tax expense. The company reported a pretax loss of -315.14M and -575.93M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Orient Europharma Co., Ltd.'s stock has declined approximately 9.69% over the past 52 weeks. The 50-day moving average sits at 46.62, while the 200-day moving average is 46.00.

Over the twelve months ended June 30, 2026, Orient Europharma Co., Ltd. generated 4.65B in revenue and converted that into -575.93M in net income, yielding earnings per share of -5.46. EBITDA reached -152.42M, while operating income came in at -337.98M.

As of June 30, 2026, Orient Europharma Co., Ltd. holds 1.55B in cash and equivalents against 3.53B in total debt, resulting in a net debt position of 1.64B. Total book value stands at 5.23B, with working capital of 555.81M providing operational flexibility.

Orient Europharma Co., Ltd. produced -602.50M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -243.15M in capital expenditures, free cash flow totaled -845.65M - equivalent to -9.77 per share.

Over the twelve months ended June 30, 2026, Orient Europharma Co., Ltd. posted a gross margin of 48.77, reflecting its pricing power and cost economics. The operating margin of -7.26 and net profit margin of -12.38 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Orient Europharma Co., Ltd. paid dividends of 1.06 per share. The dividend payout ratio of -24.97 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -21.46: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.82, meaning Orient Europharma Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Orient Europharma Co., Ltd.'s most recent stock split took place on July 28, 2010 with a 25:29 split ratio.

As of June 30, 2026, Orient Europharma Co., Ltd. has an Altman Z-Score of 1.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.